NEWSROOM

medical

Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development

Las Vegas, NV, November 23, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a Company update and recap of its concussion drug development program. Concussions represent an ‘unmet’ medical need and affect tens of millions worldwide. Odyssey acquired the intellectual property and all rights to the concussion drug in March 2021. Since the acquisition, Odyssey...

read more

Human Unitec Provides Corporate Update on Deployment Medical Equipment in Italy & Europe and update on Neutel srl contract

Boston, Massachusetts, November 15, 2022 - McapMediaWire - Human Unitec International, Inc. (OTC: HMNU) announce the new management and deployments of our HMNU Medical Equipment in Italy. We have added the following medical professional teams with Prof. Francesco Braconaro as Medical Director, Dr. Ghazy S.Amir, as a Training and Assistance Department Director, and Prof. Luciano Lanfranchi as Medical Aesthetic Department Director. The medical teams are now organized to give to the...

read more

Odyssey Health, Inc. Schedules Annual Meeting of Stockholders

Las Vegas, NV, November 15, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced it plans to  hold the Annual Meeting of Stockholders of Odyssey Health, Inc. on January 12, 2023. To be considered at the annual meeting, any stockholder proposals must be received at the principal executive offices of the Company, 2300...

read more

RemSleep Holdings Provides a Corporate Update on Testing

Tampa, FL, November 08, 2022 -- McapMediaWire -- RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever improving the level of treatment provided to obstructive Sleep Apnea patients, is pleased to announce that the expected last battery of testing will commence this week for final FDA submission of the company’s signature DeltaWave mask. The series of additional tests that were identified in the prior GXP analysis are expected to take approximately 14-18...

read more

AVRA Medical Robotics, Inc. (OTC: AVMR) Files More Patents

  ORLANDO, FL, November 03, 2022 -- McapMediaWire -- AVRA Medical Robotics, Inc. (“AVRA” or “the Company”) (OTC: AVMR) today issued the following update: In October 2022, AVRA’s patent counsel, Locke Lord LLP, filed an additional patent application related to the Company’s semi-automated robotic system. Locke Lord LLP had previously responded to the US Patent Office on a prior patent application the Company had made that covered various apparatus and methods for its semi-automated robotic...

read more

Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team

Las Vegas, NV, November 03, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, is pleased to announce its continued commitment to the newly formed entity, Odyssey NeuroPharma, with the expansion of its executive team. Joining the executive team at Odyssey NeuroPharma to advance Odyssey’s concussion treatment, and Niemann-Pick...

read more

Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Las Vegas, NV, November 01, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As announced, Odyssey’s recently completed Phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. Odyssey designed the Nasal Device with...

read more

Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases

Las Vegas, NV, October 11, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the formation of Odyssey Neuropharma, Inc., a wholly owned subsidiary, focused on developing drugs to treat neurological disorders. The blood-brain barrier (BBB) represents a significant obstacle for drug delivery to the brain. Many drugs have failed in neuroscience research due to the...

read more

Odyssey Health, Inc. Provides Recap on Concussion Drug Development

Las Vegas, NV, October 6, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a recap of their concussion drug development program. Concussions represent an ‘unmet’ medical need and affect millions worldwide. Repetitive concussions can increase the risk of developing Chronic Traumatic Encephalopathy (CTE) and other neuropsychiatric disorders. Odyssey acquired...

read more

HMNU ANNOUNCE LETTER OF INTENT FOR ASSIGNMENT OF EXCLUSIVE LICENSE FOR HOSPITAL, PORT AND AIRPORT SOLID WASTE STERILIZERS AND JOINT VENTURE WITH NEUTEL SRL

    Champlain, New York, October 5, 2022 - McapMediaWire - Human Unitec International, Inc. (OTC Pink: HMNU) (“HMNU”) is a Project Finance, Management & Development Company for Sustainability, Medical, Wellness, and Green Energy, announces strategic Letter of Intent for Exclusive License Agreement for its HMNU Medical Division. Human Unitec international is please to announce the subscription of binding letter of intent for the Exclusive License for Hospital, Port and Airport...

read more

Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program

Las Vegas, NV, Sept. 30, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing a unique drug to treat concussion has decided to dissolve its sports advisory board. The sports advisory members have been outspoken advocates for concussion prevention and for the importance of finding responsible treatments. We created the advisory board to increase awareness of our mission to bring a much-needed pharmaceutical for a...

read more

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

Las Vegas, NV, Sept. 28, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces the completion of all cohorts for its Phase I Single Ascending Dosing (SAD) and Multiple Ascending Dosing (MAD) clinical trial. Odyssey’s trial involved administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Throughout the trial, the drug was...

read more

HUMAN UNITEC INTERNATIONAL INC CORPORATE UPDATE ON MARKETING AGREEMENTS FOR ITS HMNU-MSK KINESIS MEDICAL

    Champlain, New York, September 27, 2022 - McapMediaWire - Human Unitec International, Inc. (OTC Pink: HMNU) (“HMNU”) is a Project Finance, Management & Development Company for Sustainability, Medical, Wellness, and Green Energy, announces three strategic marketing agreements for its HMNU-MSK Kinesis Medical Equipment. The Company is pleased to announce the delivery of the first shipment of 15 medical and wellness units to its exclusive agents in Italy in order to begin...

read more

Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Las Vegas, NV, Sept. 13, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for the second cohort of their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects to determine drug safety. For...

read more

Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial

  Las Vegas, NV, August 18, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For MAD Cohort I, the drug was safe and well...

read more

Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion

  Las Vegas, NV, August 10, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial. Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. MAD Cohort I subjects were dosed for five...

read more

Odyssey Health, Inc. Launches New Corporate Website

  Las Vegas, NV, August 04, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, is pleased to announce the launch of its new innovative corporate website: https://www.odysseyhealthinc.com/. The new corporate website, like the Company’s previously announced name change, was designed to not only better reflect Odyssey Health’s mission and focus, but also improve communication...

read more

RemSleep Holdings Inc. Commences Trading on OTCQB

    Tampa, FL, July 27, 2022 -- McapMediaWire -- RemSleep Holdings Inc (OTC PINK: RMSL), a medical device manufacturer dedicated to forever improving the level of treatment provided to obstructive Sleep Apnea patients, is pleased to announce that the company’s common shares will begin trading on the OTCQB Market as of the opening of the market on today, July 27, 2022. The OTCQB is the premiere marketplace for entrepreneurial and development stage U.S. and international companies that...

read more

RemSleep Holdings Inc. Engages New Senior Director for Regulatory Compliance and New Regulatory Testing Company Self Service Press Release

  Tampa, FL, July 22, 2022 -- McapMediaWire -- RemSleep Holdings Inc (OTC PINK: RMSL), a medical device manufacturer dedicated to forever improving the level of treatment provided to obstructive Sleep Apnea patients, announces the company has formally retained a new Senior Director for Regulatory Compliance and Regulatory submissions to gain FDA clearance to market the company’s medical device respiratory products. In addition, a new Regulatory Testing Company has been engaged.  Both will...

read more

Institute of Biomedical Research Corp Announces Purchase of Biomedical and Nutraceutical Assets

  SEATTLE, WA, July 22, 2022 -- McapMediaWire -- Institute of Biomedical Research Corp. (OTC Pink: MRES), a diversified biomedical company, announces the purchase of biomedical and nutraceutical assets from Wuhan General Group (China), Inc in an all-cash-transaction ("Purchase''). "This purchase is a perfect match to our business model and supports both our strategy in this sector and our direction to continue to create  a path for success for our shareholders," said Kim Halvorson,...

read more

Human Unitec International Launches Web3, Metaverse, and Blockchain based Real Estate Investment Opportunities via Tokenization of Luxury Real Estate Properties, Services, and Amenities

  Flagship Opportunities Open in Breathtaking Mediterranean Island of Sardinia, Italy   Champlain, New York, July 20, 2022 - McapMediaWire - Human Unitec International, Inc. (OTC Pink: HMNU) (“Human Unitec" “HMNU”, or the "Company") announces that on July 25, 2022, it will launch its BCPE (BlockChain Property Enterprises), a tokenization of global real estate opportunities around the world, beginning with its flagship offerings on the beautiful Mediterranean island of Sardinia, Italy...

read more

RemSleep Holdings Inc. Issues Correction to July 12th, 2022 Press Release

  Tampa, FL, July 19, 2022 -- McapMediaWire -- RemSleep Holdings Inc (OTC PINK: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive Sleep Apnea patients, provides today, an update to the Company’s press release entitled, “RemSleep Holdings Inc. Announces Acceptance and Approval of the Company’s OTCQB Application” which was issued on July 12th, 2022. In said press release, RemSleep stated, “…announced today that the company has...

read more

RemSleep Holdings Inc. Announces Acceptance and Approval of the Company’s OTCQB Application

  Tampa, FL, July 12, 2022 -- McapMediaWire -- RemSleep Holdings Inc (OTC PINK: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive Sleep Apnea patients, announced today that the company has officially received approval to be uplisted to OTCQB® status with otcmarkets.com. We anticipate OTCQB® status to be live on otcmarkets.com within 24-48 hours of this press release. The move to the OTCQB® exchange provides enhanced investor...

read more

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

  Las Vegas, NV, July 12, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions...

read more

HUMAN UNITEC INTERNATIONAL ANNOUNCES AGREEMENT WITH MEDICAL CLINICS FOR ITS MEDICAL EQUIPMENT AND AN EXCLUSIVE MARKETING AGREEMENT WITH CESANA MEDIA CHINA

    Boston, Massachusetts, July 06, 2022 - McapMediaWire - Human Unitec International, Inc., (OTC Pink: HMNU) (“HMNU”), is a Project Finance, Management & Development for Sustainability, Medical, Wellness, and Green Energy provides July 6, 2022 Corporate Status Update. ​​​​​​​​​​​Human Unitec is proud to announce the appointment of Cesana Media China, http://www.cesanamedia.cn/en/, as the exclusive marketing agent for the HMNU Medical Equipments and HMNU Medical Centers, The...

read more

Odyssey Health, Inc. Completes Safety Evaluation of Cohort II for Concussion Drug

  Las Vegas, NV, June 29, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that the drug was safe and well-tolerated. The trial is...

read more

HUMAN UNITEC INTERNATIONAL ANNOUNCES IT’S SUPPORT TO MSK KINESIS FOUNDATION FOR ITS 2022 HUMANITARIAN MISSION IN AFRICAN NATION GAMBIA

    Boston, Massachusetts, June 22, 2021 - McapMediaWire - Human Unitec International, Inc., (OTC Pink: HMNU) (“HMNU”), is a Project Finance, Management & Development for Sustainability, Medical, Wellness, and Green Energy provides Corporate Status Update. ​​​​​​​​​​​On June 6, 2022, during a meeting headed at Gambia Consulate in Milano, Italy, Professor Francesco Cristina di Santannera, Counsellor of Gambia and the Msk Kinesis Foundation Representatives finalized the program for...

read more

RemSleep Holdings Inc Addresses Shareholders

  Tampa, FL, June 16, 2022 -- McapMediaWire -- RemSleep Holdings Inc (OTC PINK: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, would like to address shareholders regarding the S-1 filing from June 15th, 2022. First and foremost, we want to be clear, we did not file the S-1 out of necessity. This was set up as a precautionary safety net given the current global and U.S. economic dynamics, and the...

read more

RemSleep Holdings Inc. Submits Application For Uplisting to OTCQB

  Tampa, FL, June 10, 2022 -- McapMediaWire -- RemSleep Holdings Inc (OTC PINK: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, today announced that the company has officially filed its application for OTCQB® status with otcmarkets.com. The company anticipates receiving a decision on the application in approximately 3-4 weeks. The Company believes that the move to the OTCQB® will provide enhanced...

read more

RedChip Interviews Odyssey Health, Inc.’s CEO Michael Redmond

  Las Vegas, NV, June 08, 2022 -- McapMediaWire -- RedChip Companies will air a new C-Level interview with Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International on The RedChip Money Report® on Bloomberg TV, this Saturday, June 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the US. RedChip’s CEO Dave Gentry interviews Odyssey’s CEO Michael Redmond in this exclusive interview, covering the questions on the mind of...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »